CN101573134B - 抗感染候选药物 - Google Patents
抗感染候选药物 Download PDFInfo
- Publication number
- CN101573134B CN101573134B CN2007800324051A CN200780032405A CN101573134B CN 101573134 B CN101573134 B CN 101573134B CN 2007800324051 A CN2007800324051 A CN 2007800324051A CN 200780032405 A CN200780032405 A CN 200780032405A CN 101573134 B CN101573134 B CN 101573134B
- Authority
- CN
- China
- Prior art keywords
- plasminogen
- mice
- plg
- bacterial
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82366506P | 2006-08-28 | 2006-08-28 | |
| US60/823,665 | 2006-08-28 | ||
| PCT/SE2007/050585 WO2008026999A2 (en) | 2006-08-28 | 2007-08-28 | Candidates against infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101573134A CN101573134A (zh) | 2009-11-04 |
| CN101573134B true CN101573134B (zh) | 2013-03-06 |
Family
ID=39136397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800324051A Active CN101573134B (zh) | 2006-08-28 | 2007-08-28 | 抗感染候选药物 |
| CN200780032092XA Expired - Fee Related CN101563100B (zh) | 2006-08-28 | 2007-08-28 | 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200780032092XA Expired - Fee Related CN101563100B (zh) | 2006-08-28 | 2007-08-28 | 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8318661B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2056864B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5566105B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101517626B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101573134B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007290881B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2662101C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2056864T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA016250B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2451015T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009002226A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008026999A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| AU2007290882B2 (en) | 2006-08-28 | 2013-02-21 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| NZ597452A (en) | 2009-07-10 | 2013-10-25 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| WO2011023805A1 (en) | 2009-08-28 | 2011-03-03 | Thrombogenics N.V. | Use of plasmin for the treatment of filtration failure after trabeculectomy |
| RU2421192C1 (ru) * | 2010-03-09 | 2011-06-20 | Винера Гумаровна Нафикова | Способ лечения хронического бактериального конъюнктивита |
| PL2598165T3 (pl) * | 2010-07-26 | 2018-02-28 | Qu Biologics Inc. | Immunogenne kompozycje przeciwzapalne |
| CA2823491A1 (en) | 2011-01-05 | 2012-07-12 | Thrombogenics Nv | Plasminogen and plasmin variants |
| CA2844644A1 (en) | 2011-08-12 | 2013-02-21 | Thrombogenics N.V. | Plasminogen and plasmin variants |
| CN102507707B (zh) * | 2011-10-12 | 2015-10-21 | 山东大学 | 一种检测龈沟液中蛋白裂解酶含量的方法 |
| CN106456740B (zh) | 2014-05-02 | 2021-06-08 | Qu生物制药公司 | 抗微生物免疫调节 |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| CN106890321A (zh) * | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防和治疗宫颈糜烂的方法 |
| EP3395355B1 (en) * | 2015-12-18 | 2026-03-04 | Talengen International Limited | Plasminogen for use in treating cervical erosion |
| EP3395354B1 (en) * | 2015-12-18 | 2024-05-22 | Talengen International Limited | Plasminogen for use in treating diabetic nephropathy |
| TWI653981B (zh) | 2015-12-18 | 2019-03-21 | 深圳瑞健生命科學硏究院有限公司 | Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury |
| TWI677347B (zh) * | 2015-12-18 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種預防和治療肝組織損傷及其相關病症的方法 |
| WO2017101871A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗心血管病的新方法 |
| JP2019500426A (ja) | 2015-12-18 | 2019-01-10 | タレンゲン インターナショナル リミティッドTalengen International Limited | 糖尿病網膜症を予防または治療するための方法 |
| CA3008466C (en) * | 2015-12-18 | 2023-06-20 | Talengen International Limited | Method for preventing or treating radiation and chemical damage |
| JP7213552B2 (ja) * | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| CN108210904A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 治疗动脉粥样硬化及其并发症的药物及其用途 |
| TWI677348B (zh) | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| WO2018107701A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种新的降血糖和提高糖耐量的药物 |
| TWI750189B (zh) | 2016-12-15 | 2021-12-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療冠狀動脈粥樣硬化及其併發症的方法 |
| CA3047170A1 (en) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for preventing and treating drug-induced renal injury |
| WO2018107689A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗脂质肾损伤的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CN107496911A (zh) * | 2017-10-20 | 2017-12-22 | 滕敏子 | 一种外科手术后用于防肿胀、抗感染的愈合剂 |
| CN113164564A (zh) * | 2018-11-19 | 2021-07-23 | 诺尔玛克Ip股份有限公司 | 用于治疗或预防心内膜炎的安克洛酶 |
| CN114174528B (zh) * | 2019-08-07 | 2025-02-21 | 学校法人东京齿科大学 | 判别方法、荧光测定装置和检查剂 |
| CN111742887A (zh) * | 2019-12-19 | 2020-10-09 | 广西医科大学第一附属医院 | 放疗后分泌性中耳炎树鼩模型的建立方法 |
| EP4094776A4 (en) * | 2020-02-11 | 2023-05-17 | Talengen International Limited | METHODS AND MEDICATIONS FOR THE TREATMENT OF VIRAL PENMONIA |
| WO2021180068A1 (zh) * | 2020-03-09 | 2021-09-16 | 泰伦基国际有限公司 | 一种治疗2019新型冠状病毒引发疾病的方法和药物 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| CN115845036B (zh) * | 2023-02-20 | 2023-05-09 | 滨州益洁口腔有限公司 | 用于口腔种植体牙龈组织的蛋白酶及制备方法 |
| JP2026526789A (ja) * | 2023-07-20 | 2026-08-10 | カトリック ユニヴェルシテット ルーヴェン | ブドウ球菌性膿瘍の治療 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003020297A2 (en) * | 2001-09-06 | 2003-03-13 | Omnio Ab | Method of improving wound healing |
| WO2003045466A2 (en) * | 2001-11-26 | 2003-06-05 | Genentech, Inc. | Catheter composition and uses thereof |
| WO2003066842A2 (de) * | 2002-02-06 | 2003-08-14 | Trommsdorff Gmbh & Co. Kg Arzneimittel | Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3023143A (en) * | 1959-10-14 | 1962-02-27 | American Cyanamid Co | Process for preparing a veterinary composition |
| AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| US5792835A (en) | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
| US5397578A (en) * | 1994-03-29 | 1995-03-14 | Tovarischestvo S Ogranichennoi Otvetstvennostiju "Taurus" | Method of treatment of chronic purulent inflammations of ear in children |
| US6372473B1 (en) | 1997-05-28 | 2002-04-16 | Human Genome Sciences, Inc. | Tissue plasminogen activator-like protease |
| US6420622B1 (en) * | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| AU5390699A (en) | 1998-07-24 | 2000-02-14 | Pharmacal Biotechnologies, Inc. | Osseous tissue reconstruction system and method |
| WO2000051538A1 (en) | 1999-03-01 | 2000-09-08 | Uab Research Foundation | Porous tissue scaffolding materials and uses thereof |
| US20030026794A1 (en) * | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
| CN1420126A (zh) | 2002-07-10 | 2003-05-28 | 牛勃 | 一种重组人纤溶酶原Kringle5突变体蛋白rhPK-5的制备方法 |
| AU2007290882B2 (en) | 2006-08-28 | 2013-02-21 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
-
2007
- 2007-08-28 CA CA2662101A patent/CA2662101C/en not_active Expired - Fee Related
- 2007-08-28 US US12/439,517 patent/US8318661B2/en active Active
- 2007-08-28 EA EA200970233A patent/EA016250B1/ru not_active IP Right Cessation
- 2007-08-28 CN CN2007800324051A patent/CN101573134B/zh active Active
- 2007-08-28 AU AU2007290881A patent/AU2007290881B2/en not_active Ceased
- 2007-08-28 EP EP07794195.3A patent/EP2056864B1/en not_active Not-in-force
- 2007-08-28 MX MX2009002226A patent/MX2009002226A/es active IP Right Grant
- 2007-08-28 CN CN200780032092XA patent/CN101563100B/zh not_active Expired - Fee Related
- 2007-08-28 DK DK07794195.3T patent/DK2056864T3/en active
- 2007-08-28 KR KR1020097005738A patent/KR101517626B1/ko not_active Expired - Fee Related
- 2007-08-28 ES ES07794195.3T patent/ES2451015T3/es active Active
- 2007-08-28 WO PCT/SE2007/050585 patent/WO2008026999A2/en not_active Ceased
- 2007-08-28 JP JP2009526572A patent/JP5566105B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-26 US US13/685,466 patent/US20130149321A1/en not_active Abandoned
-
2015
- 2015-12-09 US US14/964,481 patent/US10729750B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003020297A2 (en) * | 2001-09-06 | 2003-03-13 | Omnio Ab | Method of improving wound healing |
| WO2003045466A2 (en) * | 2001-11-26 | 2003-06-05 | Genentech, Inc. | Catheter composition and uses thereof |
| WO2003066842A2 (de) * | 2002-02-06 | 2003-08-14 | Trommsdorff Gmbh & Co. Kg Arzneimittel | Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2662101A1 (en) | 2008-03-06 |
| KR101517626B1 (ko) | 2015-05-07 |
| CN101563100B (zh) | 2013-08-07 |
| JP5566105B2 (ja) | 2014-08-06 |
| EP2056864B1 (en) | 2013-12-11 |
| US20100099600A1 (en) | 2010-04-22 |
| ES2451015T3 (es) | 2014-03-26 |
| US10729750B2 (en) | 2020-08-04 |
| US20160243204A1 (en) | 2016-08-25 |
| EA200970233A1 (ru) | 2009-08-28 |
| US8318661B2 (en) | 2012-11-27 |
| EP2056864A4 (en) | 2012-01-25 |
| WO2008026999A3 (en) | 2008-05-22 |
| KR20090059122A (ko) | 2009-06-10 |
| CA2662101C (en) | 2015-07-07 |
| US20130149321A1 (en) | 2013-06-13 |
| JP2010502600A (ja) | 2010-01-28 |
| EA016250B1 (ru) | 2012-03-30 |
| WO2008026999A2 (en) | 2008-03-06 |
| AU2007290881A1 (en) | 2008-03-06 |
| CN101563100A (zh) | 2009-10-21 |
| CN101573134A (zh) | 2009-11-04 |
| EP2056864A2 (en) | 2009-05-13 |
| DK2056864T3 (en) | 2014-03-10 |
| MX2009002226A (es) | 2009-09-07 |
| AU2007290881B2 (en) | 2013-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5566105B2 (ja) | 感染症に対する候補薬 | |
| CN1961958B (zh) | 改善伤口愈合的方法 | |
| Knight et al. | Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma | |
| Lewis | Expanding the clinical indications for α1-antitrypsin therapy | |
| US8716218B2 (en) | Extracellular histones as biomarkers for prognosis and molecular targets for therapy | |
| JP6186427B2 (ja) | 抗菌性ファージのカクテルを含む組成物及び細菌感染症を処置するためのその使用 | |
| Zhang et al. | Evaluation of breviscapine on prevention of experimentally induced abdominal adhesions in rats | |
| Fan et al. | Annexin A2 plus low-dose tissue plasminogen activator combination attenuates cerebrovascular dysfunction after focal embolic stroke of rats | |
| JP2020186263A (ja) | 放射性および化学的損傷を予防及び治療するための方法 | |
| Gabre et al. | Activated protein C accelerates venous thrombus resolution through heme oxygenase‐1 induction | |
| WO2017101869A1 (zh) | 一种预防和治疗肝组织损伤及其相关病症的方法 | |
| EP3395355B1 (en) | Plasminogen for use in treating cervical erosion | |
| HK1136204A (en) | Candidates against infection | |
| KR20140004620A (ko) | 초기 면역 방어에 있어서 신규한 기능을 발휘하는 선구 세린 프로테아제 응고 캐스케이드 | |
| CN101541829A (zh) | 来自丝光绿蝇的胰凝乳蛋白酶及其在治疗伤口中的用途 | |
| Johnson et al. | Plasminogen activator inhibitor type-2 (PAI-2)/SerpinB2: a unique multifunctional serpin | |
| Guery et al. | Apoptosis in Pneumonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1136204 Country of ref document: HK |
|
| ASS | Succession or assignment of patent right |
Owner name: WYF INNOVATION UMEA AB Free format text: FORMER OWNER: OMNIO HEALER AB Effective date: 20121130 Owner name: WANG TIANGANG Effective date: 20121130 Owner name: LI JINAN Free format text: FORMER OWNER: WYF INNOVATION UMEA AB Effective date: 20121130 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; TO: 100000 CHAOYANG, BEIJING |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20121130 Address after: 100000, Beijing, Chaoyang District Zhuang Jia Zhuang No. 8 (booming Park South Gate) Rui Jian International Nursing Applicant after: Li Jinan Applicant after: Wang Tiangang Address before: Swedish chicken Applicant before: WYF innovation excellence Co. Effective date of registration: 20121130 Address after: Swedish chicken Applicant after: WYF innovation excellence Co. Address before: Swedish chicken Applicant before: Omni Treatment Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENZHEN TIANRUI RENJIAN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LI JINAN Effective date: 20140714 Free format text: FORMER OWNER: WANG TIANGANG Effective date: 20140714 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100000 CHAOYANG, BEIJING TO: 518057 SHENZHEN, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140714 Address after: 518057, No. 13, building 11, overseas student building, 29 South Ring Road, Nanshan District hi tech Zone, Guangdong, Shenzhen Patentee after: Shenzhen days of Kin Kin Kin Biological Technology Co.,Ltd. Address before: 100000, Beijing, Chaoyang District Zhuang Jia Zhuang No. 8 (booming Park South Gate) Rui Jian International Nursing Patentee before: Li Jinan Patentee before: Wang Tiangang |
|
| ASS | Succession or assignment of patent right |
Owner name: SHENZHEN RUIJIAN LIFE SCIENCES INSTITUTE CO., LTD. Free format text: FORMER OWNER: SHENZHEN TIANRUI RENJIAN BIOTECHNOLOGY CO., LTD. Effective date: 20150320 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 518057 SHENZHEN, GUANGDONG PROVINCE TO: 518000 SHENZHEN, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150320 Address after: 518000, Guangdong, Shenzhen, Futian District Futian street, Shennan Road, No. 1006, Shenzhen International Innovation Center, C building, 19 floor, 19-002 Patentee after: TALENGEN INSTITUTE OF LIFE SCIENCES, Co.,Ltd. Address before: 518057, No. 13, building 11, overseas student building, 29 South Ring Road, Nanshan District hi tech Zone, Guangdong, Shenzhen Patentee before: Shenzhen days of Kin Kin Kin Biological Technology Co.,Ltd. |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1136204 Country of ref document: HK |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20200106 Address after: Unit 702, unit 1, building 1, Zhongtai community, No. 2088, Honggui Road, Guiyuan street, Luohu District, Shenzhen City, Guangdong Province Patentee after: Shenzhen days of Kin Kin Kin Biological Technology Co.,Ltd. Address before: 518000, Guangdong, Shenzhen, Futian District Futian street, Shennan Road, No. 1006, Shenzhen International Innovation Center, C building, 19 floor, 19-002 Patentee before: TALENGEN INSTITUTE OF LIFE SCIENCES, Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220624 Address after: 075061 No. 101, unit 2, building 12, xiadongying, Qiaoxi District, Zhangjiakou City, Hebei Province Patentee after: Zhu Xu Address before: 518057 room 702, unit 1, building 1, Zhongtai community, 2088 Honggui Road, Guiyuan street, Luohu District, Shenzhen City, Guangdong Province Patentee before: Shenzhen days of Kin Kin Kin Biological Technology Co.,Ltd. |